Pharyngitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Pharyngitis Market Outlook
Thelansis’s “Pharyngitis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Pharyngitis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Pharyngitis Overview
Pharyngitis
is a condition where the mucous membranes of the oropharynx become inflamed.
The most common cause of pharyngitis is an infection, either bacterial or
viral. Other less common causes include allergies, trauma, cancer, reflux, and
certain toxins. Viral infections account for about 50% to 80% of pharyngitis
cases. Various viral pathogens, including rhinovirus, influenza, adenovirus,
coronavirus, and parainfluenza, cause these infections. Less common viral
pathogens include herpes, Epstein-Barr virus, human immunodeficiency virus
(HIV), and coxsackievirus. Bacterial infections are more severe and may develop
after an initial viral infection. The most common bacterial infection is Group
A beta-hemolytic streptococci, which causes 5% to 36% of cases of acute
pharyngitis. Penicillin is the preferred antibiotic for treating Group A
beta-hemolytic streptococcal (GAS) pharyngitis1. GAS pharyngitis is uncommon in
preschool-aged children and adults.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment